Murray-Smith, Heidi
Barker, Suzie
Barkhof, Frederik
Barnes, Josephine
Brown, Thomas M.
Captur, Gabriella
R.E.Cartlidge, Molly
Cash, David M.
Coath, William
Davis, Daniel
Dickson, John C.
Groves, James
Hughes, Alun D.
James, Sarah-Naomi
Keshavan, Ashvini
Keuss, Sarah E.
King-Robson, Josh
Lu, Kirsty
Malone, Ian B.
Nicholas, Jennifer M.
Rapala, Alicja
Scott, Catherine J.
Street, Rebecca
Sudre, Carole H.
Thomas, David L.
Wong, Andrew
Wray, Selina
Zetterberg, Henrik
Chaturvedi, Nishi
Fox, Nick C.
Crutch, Sebastian J.
Richards, Marcus
Schott, Jonathan M.
Article History
Received: 30 August 2023
Accepted: 13 November 2023
First Online: 23 January 2024
Declarations
:
: The study was approved by the Health Research Authority Research Ethics Committee (HRA REC) London (REC reference 14/LO/1173, PI Schott). Subsequently, we have received approval for three substantial and ten non-substantial amendments that reflect the changes described in the present document. All participants provide written informed consent to participate at the beginning of each of the three phases, in accordance with the Declaration of Helsinki, and for their data to be stored in accordance with the Data Protection Act (2018) and General Data Protection Regulations (GDPR).
: Not applicable.
: FB serves on the steering committee or data safety monitoring board member for Biogen, Merck, ATRI/ACTC and Prothena. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen, and Combinostics. FB also has research agreements with Merck, Biogen, GE Healthcare, Roche. FB is the co-founder and shareholder of Queen Square Analytics LTD. JB serves on the Alzheimer’s Association Vascular Cognitive Disorders Professional Interest Area Committee. CHS is a scientific advisor to BrainKey. NC participates on a Data Safety and Monitoring Board for AstraZeneca. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). NF served on scientific advisory boards and/or as a consultant for Biogen, Eli Lilly, Ionis, Roche and Siemens (all payments to UCL) and has participated on a Data Safety Monitoring Board for Biogen. JS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); consulted for Roche Pharmaceuticals, Biogen, Merck, and Eli Lilly; given educational lectures sponsored by GE Healthcare, Eli Lilly, and Biogen; and is Chief Medical Officer for ARUK. HM-S, SB, TB, GC, MC, DC, WC, DD, JD, JG, AH, S-NJ, AK, SK, JK-R, KL, IM, JN, AR, CJS, RS, DT, AW, SW, NC, SC, and MR do not have any conflicts of interest to declare.